


Retrievable & Permanent


PROVEN & RELIABLE



Cordis[™]
A Cardinal Health company


OPTEASE[™]
Retrievable Vena Cava Filter

Leave It In. Take It Out. Your Choice. Our Advantage.




Versatility

- Low profile, 6F delivery system
- Six potential access points
- Caval coverage up to 30 mm



Retrievable or Permanent

- Removal is optional for up to 12 days
- Robust design for long term durability
- Design helps reduce risks known to retrievable filters



Safe Profile

- Demonstrated low complication rates across multiple clinical studies
- PROOF results demonstrate low rate of complications when left permanently

FDA Recommendations for Retrieval

Shorter
Retrieval
Window

FDA Recommendation¹: Between **1 and 2 months** the risk-benefit profile favors removal of the filter if the patient's transient risk for PE has passed.

The Cordis Solution:
The Cordis OPTEASE™
Retrievable Vena Cava Filter
can be removed up to 12 days
from the date of implantation
and is proven to have low
complication rates.

Cordis
OPTEASE™
Retrievable Vena Cava Filter
LOW
Complication
Rates

The Problem:

In 2014, the FDA issued a Safety Communication highlighting concern about adverse events reported with vena cava filters, noting that

some complications may

be related to indwell


time including:

- Filter Embolization
- IVC Penetration
- Filter Fracture
- Filter Migration
- Retrieval Complications

Designed to Deliver Performance and Stability for Every Patient

Six Insertion Sites

For ease of use including femoral, jugular and antecubital veins bilaterally



Fixation Barbs

Minimize migration to maintain clot capture efficiency

Closed Cage

Designed to eliminate risk of caval perforation and strut embolization

Eliminates risk of arm entanglement

Side Struts

Self centering upon insertion reduces the risk of tilting

Dual Prong Caudal Hook

For easier snare capture

Fixation Barbs




- Minimize risk of migration to maintain clot capture efficiency
- “Ski Barb” design resists cranial migration which can lead to serious complications
- Location at upper pole allows for earlier wall apposition when placed via femoral access

Dual Prong Claudal Hook




- Dual prong hook designed for easier snare capture
- Femoral retrieval route avoids passing through the heart
- 12 day retrieval

Side Struts



- Self centering upon insertion, reducing the risk of tilting which can decrease clot capture efficiency
- Dual Prong Caudal Hook for easier capture with any appropriate endovascular snare
- Minimize risk of migration providing caval wall contact earlier in the deployment process than other designs

Closed Cage Design





- Fully connected structure designed to eliminate the risk of caval perforation by needle-like arms
- Designed to eliminate strut embolization after fracture of a single strut segment
- Eliminates risk of struts becoming entangled, thereby leaving a gap between struts

Here's the PROOF Study results: A Demonstration of Safety that Results in Confidence

In the prospective, multi-center, single filter, trial with 150 patients at 11 U.S. sites, the **OPTEASE™** Vena Cava Filter had no reports of symptomatic PE, caval perforation or strut embolization¹.

Results from this study show that the **OPTEASE™** Retrievable Vena Cava Filter can be safely used as a permanent filter in patients at high risk for pulmonary embolism.



Fewer than 1% of patients experienced filter migration or new thrombus formation with the **OPTEASE™** Retrievable Vena Cava Filter.

One of The Most Tested Filter on The Market

OPTEASE™

Retrievable Vena Cava Filter

PROOF Trial: Protection from Pulmonary Embolism with the Cordis OPTEASE™ Retrievable Vena Cava Filter¹

Prospective, multi-center, single filter with 150 patients enrolled at 11 U.S. sites

PE Protection

Symptomatic PE

1 Month (n=111).....	0.0%
6 Month (n=70).....	0.0%

Low Complications

Caval Perforation

1 Month (n=111).....	0.0%
6 Month (n=70).....	0.0%

Filter Migration

1 Month (n=111).....	0.9% (1 Case)
6 Month (n=70).....	No New Cases

Symptomatic Filter Thrombosis

1 Month (n=111).....	0.8% (1 Case)
6 Month (n=70).....	No New Cases

[Click Here](#) for PROOF Publication

OPTEASE™ Retrievable Vena Cava Filter

Cordis OPTEASE™ Retrievable Vena Cava Filter Ordering Information

Description	Access Site	Catalog Numbers
Cordis OPTEASE™ Vena Cava Filter and Introduction Kit (55 cm)	Femoral	466-F210AF
Cordis OPTEASE™ Vena Cava Filter and Introduction Kit (55 cm)	Jugular	466-F210AJ
Cordis OPTEASE™ Vena Cava Filter and Introduction Kit (90 cm)	Antecubital, Jugular	466-F210BJ

¹Ziegler, JW et al. PROOF Trial: Protection from Pulmonary Embolism with the OPTEASE™ Filter. JVIR 2008; 19:1165-1170.

WARNING: Implant of the OPTEASE™ Vena Cava Filter with the hook oriented in the cranial direction can result in life threatening or serious injury including, but not limited to dissection, vessel perforation, migration of the filter with secondary damage to cardiac structures, ineffective pulmonary embolism prevention or death.

For healthcare professionals only. Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, suggested procedure, warnings and precautions. As part of its continuous product development policy, Cordis reserves the right to change product specifications without prior notification.

CORDIS, Cordis LOGO, OPTEASE are trademarks of Cardinal Health and may be registered in the US and/or in other countries. All other marks are the property of their respective owners. © 2019 Cardinal Health. All Rights Reserved. 04/19 - 100535069



Cordis[™]
A Cardinal Health company